SG10201707768RA - Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation - Google Patents

Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation

Info

Publication number
SG10201707768RA
SG10201707768RA SG10201707768RA SG10201707768RA SG10201707768RA SG 10201707768R A SG10201707768R A SG 10201707768RA SG 10201707768R A SG10201707768R A SG 10201707768RA SG 10201707768R A SG10201707768R A SG 10201707768RA SG 10201707768R A SG10201707768R A SG 10201707768RA
Authority
SG
Singapore
Prior art keywords
methyl
imidazol
pyridinyl
pyrimidinyl
trifluoromethyl
Prior art date
Application number
SG10201707768RA
Other languages
English (en)
Inventor
Upkar Bhardwaj
Mangesh Sadashiv Bordawekar
Ann Reese Comfort
Ping Li
Shoufeng Li
Alexey Makarov
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG10201707768RA publication Critical patent/SG10201707768RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG10201707768RA 2011-11-14 2012-11-12 Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation SG10201707768RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161559281P 2011-11-14 2011-11-14

Publications (1)

Publication Number Publication Date
SG10201707768RA true SG10201707768RA (en) 2017-10-30

Family

ID=47324402

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201707768RA SG10201707768RA (en) 2011-11-14 2012-11-12 Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
SG11201401476TA SG11201401476TA (en) 2011-11-14 2012-11-12 Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201401476TA SG11201401476TA (en) 2011-11-14 2012-11-12 Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation

Country Status (22)

Country Link
EP (1) EP2779995A1 (fr)
JP (1) JP6275645B2 (fr)
KR (1) KR20140093230A (fr)
CN (1) CN103930094A (fr)
AR (1) AR088844A1 (fr)
BR (1) BR112014011518A2 (fr)
CA (1) CA2855503A1 (fr)
CL (1) CL2014001247A1 (fr)
CO (1) CO6960546A2 (fr)
EA (1) EA201490960A1 (fr)
GT (1) GT201400094A (fr)
HK (1) HK1197025A1 (fr)
IL (1) IL232480A0 (fr)
IN (1) IN2014DN03416A (fr)
MA (1) MA35636B1 (fr)
MX (1) MX2014005874A (fr)
PE (1) PE20141337A1 (fr)
SG (2) SG10201707768RA (fr)
TN (1) TN2014000177A1 (fr)
TW (1) TWI574690B (fr)
WO (1) WO2013074432A1 (fr)
ZA (1) ZA201402756B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792360A1 (fr) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide pour utilisation dans le traitement de HCV
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
JP7378279B2 (ja) * 2019-11-18 2023-11-13 日本化薬株式会社 ニロチニブを有効成分とする医薬錠剤及びその製造方法
JP7489849B2 (ja) 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
EP1923053A1 (fr) * 2006-09-27 2008-05-21 Novartis AG Composition pharmaceutique comprenant de la nilotinib ou son sel
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
WO2012164578A1 (fr) * 2011-06-02 2012-12-06 Hetero Research Foundation Compositions et procédés de préparation de formulations de nilotinib à libération immédiate

Also Published As

Publication number Publication date
CO6960546A2 (es) 2014-05-30
KR20140093230A (ko) 2014-07-25
CL2014001247A1 (es) 2014-10-17
ZA201402756B (en) 2015-04-29
EA201490960A1 (ru) 2014-08-29
GT201400094A (es) 2017-09-28
NZ623844A (en) 2016-09-30
TWI574690B (zh) 2017-03-21
CA2855503A1 (fr) 2013-05-23
MX2014005874A (es) 2014-06-23
TN2014000177A1 (en) 2015-09-30
CN103930094A (zh) 2014-07-16
SG11201401476TA (en) 2014-10-30
AR088844A1 (es) 2014-07-10
BR112014011518A2 (pt) 2017-05-16
TW201325594A (zh) 2013-07-01
AU2012339829A1 (en) 2014-05-29
IL232480A0 (en) 2014-06-30
JP2014533283A (ja) 2014-12-11
IN2014DN03416A (fr) 2015-06-26
HK1197025A1 (en) 2015-01-02
MA35636B1 (fr) 2014-11-01
JP6275645B2 (ja) 2018-02-07
PE20141337A1 (es) 2014-10-16
AU2012339829B2 (en) 2016-05-12
EP2779995A1 (fr) 2014-09-24
WO2013074432A1 (fr) 2013-05-23

Similar Documents

Publication Publication Date Title
IL229395A0 (en) Adjusted release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-4)-5-n-methyl-h1 imidazol-1-yl)-3-(trifluoromethyl)phenyl] Benzamide is dissolved using organic acids
ZA201101891B (en) The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
HK1226069A1 (zh) 3，5 -二氨基-6-氯-n-(n-(4 -(4 -(2 -(己基(2，3，4，5，6 -五羥基己基)氨基)乙氧基)苯基)丁基)甲脒基)吡嗪-2-甲醯胺
HK1217487A1 (zh) 用於治療成癮的作為乙醛脫氫酶- 抑制劑的 -氧基- -二氫-吡啶- -基 -芐基 -苯甲酰胺衍生物
IL236495A0 (en) Heteroaromatic compounds as proton tyrosine kinase inhibitors
ME02307B (me) Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol- 3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr
DK2878598T3 (da) Krystallinsk form af 4-[5-(pyridin-4-yl)-1h-1,2,4-triazol-3-yl]pyridin-2-carbonitril
IL237378B (en) Derivatives of 1-(phenyl/pyrid-4-yl)-3-(phenyl-oxazolyl-5-(methyl-4,2,1,-triazole) and pharmaceutical compounds containing them
IL254132B (en) A solid preparation of N-(4-(1(2,6-difluorobenzyl)-5-))dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxy-1,2,3 4-tetrahydrothiano[2,3-d]pyrimidine-6-yl)phenyl)-n-methoxyurea or its salt
HK1202237A1 (zh) -二氯- -苯並 咪唑- -基 -吡唑- -羧酸的葡甲胺鹽製劑
WO2013150545A3 (fr) Procédés de préparation de dérivés de benzimidazole et de sels de ceux-ci
IL225704A (en) Polymorphs and salts of 6– (1 h– indole – 4 – ram) –4– (5 - {[4– (1-methylethyl) –1 – piperazine] methyl} –1,3 – oxazole – 2 – ram) –1 h- Indazole as pi3k inhibitors for use in treating respiratory problems
SG11201405592TA (en) Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one
IL220851A (en) Process for the preparation of n - (2 - (2 - (4 - (2 - (7,6-dimethoxy-4,3-dihydro-iso-quinoline-2 - (1 h))) ethyl) phenyl) - h2 - tetrazole - 5-ram (5,4-dimethoxyphenyl) -4-oxo-h4-chromium-2-carboxamide methane-sulfonate, its intermediate and intermediate preparation process
HK1197025A1 (en) Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide formulation 4--3[[4-(3-)-2-]]-n-[5-(4--1h--1- )-3-()]
SI2608789T1 (sl) Terapevtske uporabe 1-(2-(2,4-dimetil-fenilsulfanil) fenil) piperazina
PT2943488T (pt) Formas de sal de meglumina do ácido 2-((1r,4r)-4-(4-(5- (benzoxazol-2-ilamina)piridin-2-il)fenil)ciclohexil) acético e sua utilização como inibidores de dgat1
PL394559A1 (pl) Kapsulki zawierajace 4-[(4-metylopiperazyn-1ylo)metylo]-N-[4-metylo-3-[(4-pirydyn-3-ylopirymidyn-2-ylo)amino]fenylo]benzamid oraz sposób jej wytwarzania
PL392269A1 (pl) Tabletka zawierająca 4-[(4-metylopiperazyn-1-ylo)metylo]-N-[4-metylo-3-[(4-pirydyn-3-ylopirymidyn-2-ylo)amino]fenylo]benzamid oraz sposób jej wytwarzania
PL387516A1 (pl) Kompozycja farmaceutyczna zawierająca 4-[(4-metylopiperazyn-1-ylo)metylo]-N-[4-metylo-3-[(4-pirydyn-3-ylopirymidyn-2-ylo)amino]fenylo]benzamid, sposób jej wytwarzania oraz postacie leku zawierające tę kompozycję